Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-18 4:59 pm Purchase | 2025-02-10 | 13D | Sionna Therapeutics, Inc. SION | Atlas Venture Fund XI, L.P. | 2,886,293 6.500% | 2,886,293 (New Position) | Filing History |
| 2024-11-14 4:32 pm Sale | 2024-09-30 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI, L.P. | 5,714,057 5.700% | -1,628,026 (-22.17%) | Filing History |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | Xilio Therapeutics, Inc. XLO | Atlas Venture Fund XI, L.P. | 0 0.000% | -2,023,402 (Position Closed) | Filing History |
| 2024-11-14 4:30 pm Sale | 2024-09-30 | 13G | Day One Biopharmaceuticals, Inc. DAWN | Atlas Venture Fund XI, L.P. | 4,869,681 5.500% | -1,178,137 (-19.48%) | Filing History |
| 2024-11-05 6:26 pm Sale | 2024-11-01 | 13D | Third Harmonic Bio, Inc. THRD | Atlas Venture Fund XI, L.P. | 9,808,190 23.900% | -505,573 (-4.90%) | Filing History |
| 2024-02-09 4:09 pm Purchase | 2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI, L.P. | 7,342,083 9.100% | 15,966 (+0.22%) | Filing History |
| 2024-02-09 4:08 pm Purchase | 2023-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN | Atlas Venture Fund XI, L.P. | 6,047,818 6.900% | 39,284 (+0.65%) | Filing History |
| 2023-11-13 4:15 pm Purchase | 2023-11-03 | 13D | Korro Bio, Inc. KRRO | Atlas Venture Fund XI, L.P. | 942,075 11.800% | 942,075 (New Position) | Filing History |
| 2023-02-14 4:31 pm Sale | 2022-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI, L.P. | 467,529 1.000% | -1,496,000 (-76.19%) | Filing History |
| 2023-02-14 4:29 pm Unchanged | 2022-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI, L.P. | 7,326,117 14.100% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:23 pm Sale | 2022-12-31 | 13G | Day One Biopharmaceuticals, Inc. DAWN | Atlas Venture Fund XI, L.P. | 6,008,534 8.200% | -1,201,708 (-16.67%) | Filing History |
| 2022-09-29 4:30 pm Purchase | 2022-09-19 | 13D | Third Harmonic Bio, Inc. THRD | Atlas Venture Fund XI, L.P. | 10,313,763 25.600% | 10,313,763 (New Position) | Filing History |
| 2022-02-11 5:04 pm Sale | 2021-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI, L.P. | 7,326,117 14.200% | -814,013 (-10.00%) | Filing History |
| 2022-02-11 5:03 pm Sale | 2021-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI, L.P. | 1,963,529 5.600% | -242,883 (-11.01%) | Filing History |
| 2022-02-11 5:03 pm Purchase | 2021-06-01 | 13G | Day One Biopharmaceuticals, Inc. DAWN | Atlas Venture Fund XI, L.P. | 7,210,242 11.600% | 7,210,242 (New Position) | Filing History |
| 2021-11-05 4:43 pm Purchase | 2021-10-26 | 13G | Xilio Therapeutics, Inc. XLO | Atlas Venture Fund XI, L.P. | 2,023,402 7.600% | 2,023,402 (New Position) | Filing History |
| 2021-02-16 5:28 pm Purchase | 2020-12-31 | 13G | Dyne Therapeutics, Inc. DYN | Atlas Venture Fund XI, L.P. | 8,140,130 17.900% | 8,140,130 (New Position) | Filing History |
| 2021-02-16 5:27 pm Sale | 2020-12-31 | 13G | Akero Therapeutics, Inc. AKRO | Atlas Venture Fund XI, L.P. | 2,206,412 6.400% | -500,000 (-18.47%) | Filing History |